<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048278</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1365</org_study_id>
    <nct_id>NCT04048278</nct_id>
  </id_info>
  <brief_title>Lidocaine Infusion in Pancreatic Cancer</brief_title>
  <official_title>Lidocaine Infusion in Pancreatic Cancer: Translational Studies in a Preclinical Model And Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology
      of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic
      pancreatectomy for all types of pancreatic cancer.

      A prospective randomized controlled double blinded trial design will be used for the proposed
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the effect of IV lidocaine infusion on
      various enzymatic activities and associated pathways in isolated CTCs as well as the number
      of CTCs during the perioperative period in patients undergoing robotic pancreatectomy for
      pancreatic cancer. It is expected that by downregulating the pathways by lidocaine might
      affect the enzymatic activity in those CTCs as well as the number of CTCs in the circulation.

      A prospective randomized controlled double blinded trial design will be used for the proposed
      study.

      Patients undergoing robotic pancreatectomy for pancreatic cancer will be randomized (ratio
      1:1) into two groups: one group will receive a 24-h normal saline infusion and the second
      group will receive a 24-h lidocaine infusion. Blood samples will be collected in different
      times perioperatively in order to evaluate the objectives of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 8, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective randomized placebo-controlled double blinded trial design will be used for the proposed study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Both patients and the physicians performing the cases will be unaware of who receives lidocaine or placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Specimen outcome measure.</measure>
    <time_frame>Outcomes will be evaluated perioperatively</time_frame>
    <description>Src Tyrosine Kinase Enzymatic activity in CTCs. Fluorescence intensity will be used to measure Src phosphorylation in circulating tumor cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specimen outcome measure.</measure>
    <time_frame>Outcomes will be evaluated perioperatively</time_frame>
    <description>Cytokine Levels in Serum (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specimen outcome measure.</measure>
    <time_frame>Outcomes will be evaluated perioperatively</time_frame>
    <description>Chemokine levels in serum (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upregulation or Downregulation of Gene Expression.</measure>
    <time_frame>Outcomes will be evaluated perioperatively</time_frame>
    <description>Upregulation or downregulation of gene expression will be measured with the Real Time (RT) square Profiler Polimerase Chain Reaction (PCR )Array Analysis, and Real Time PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specimen outcome measure</measure>
    <time_frame>Perioperatively</time_frame>
    <description>CTCs Enumeration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Lidocaine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The IV bolus and infusions of lidocaine to those patients assigned to the lidocaine group will be started in the operating room and will continue until 24 h later. The group receiving the lidocaine infusion will first be administered a 1.0 - 1.5 mg/kg loading infusion over 5 minutes followed by a 1.0 - 1.5 mg/kg/h infusion for 24 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Solution for Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The group receiving the saline infusion will be administered an equivalent volume of saline infused over 5 min followed by a saline infusion at the same flow rate as that used in the lidocaine group for 24 h (1.0 - 1.5 mg/kg/hr)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Hydrochloride</intervention_name>
    <description>IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control</description>
    <arm_group_label>Lidocaine Hydrochloride</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution for Injection</intervention_name>
    <description>IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control</description>
    <arm_group_label>Saline Solution for Injection</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has histologically or cytologically confirmed adenocarcinoma of the pancreas that is
             considered resectable as well as other types of pancreatic cancer (malignant endocrine
             and exocrine tumors)

          2. Has measurable disease, defined as at least 1 tumor that fulfills the criteria

          3. Patients diagnosed with resectable cancer, but upon initial phase of surgical
             exploration found to have metastatic disease

          4. Has read, understood and signed the informed consent form (ICF) approved by the
             Independent Review Board/Independent Ethics Committee (IRB/IEC)

          5. Prior systemic treatments for metastatic disease are permitted, including targeted
             therapies, biologic response modifiers, chemotherapy, hormonal therapy, or
             investigational therapy.

        Exclusion Criteria:

          1. Has American Society of Anesthesiologists (ASA) physical status &gt; 3

          2. Has hypersensitivity or allergy to amide-linked local anesthetics

          3. Has a second or third degree heart block

          4. Has severe sinoatrial block

          5. Is currently being treated with any of the following class I antiarrhythmic drugs;
             quinidine, flecainide, disopyramide, or procainamide

          6. Has been treated with amiodarone in the past

          7. Has Adams-Stoke syndrome

          8. Has Wolff-Parkinson-White syndrome

          9. Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless
             controlled by anticoagulant treatment

         10. Has a known history of human immunodeficiency virus (HIV) positivity or untreated and
             uncontrolled hepatitis B or C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina E. Votta-Velis, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Barabanova, MS</last_name>
    <phone>(312)996-4020</phone>
    <email>barabano@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gina E. Votta-Velis, MD PhD</last_name>
    <phone>(312)996-4020</phone>
    <email>barabano@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Illnois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina E Votta-Velis, MD PhD</last_name>
      <phone>312-996-4020</phone>
      <email>ginavot@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Barabanova, MS</last_name>
      <phone>(312)355-5733</phone>
      <email>barabano@uic.edu</email>
    </contact_backup>
    <investigator>
      <last_name>E. Gina Votta-Velis, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ajay Rana, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pier C. Giulianotti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain A. Borgeat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandeep Kumar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Gangemi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003 Oct;10(8):972-92. Review.</citation>
    <PMID>14527919</PMID>
  </reference>
  <reference>
    <citation>Mokbel K, Choy C, Engledow A. The effect of surgical wounding on tumour development. Eur J Surg Oncol. 2000 Mar;26(2):195.</citation>
    <PMID>10744945</PMID>
  </reference>
  <reference>
    <citation>Missair A, Cata JP, Votta-Velis G, Johnson M, Borgeat A, Tiouririne M, Gottumukkala V, Buggy D, Vallejo R, Marrero EB, Sessler D, Huntoon MA, Andres J, Casasola OL. Impact of perioperative pain management on cancer recurrence: an ASRA/ESRA special article. Reg Anesth Pain Med. 2019 Jan;44(1):13-28. doi: 10.1136/rapm-2018-000001. Review.</citation>
    <PMID>30640648</PMID>
  </reference>
  <reference>
    <citation>Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Tumour Biol. 2014 Mar;35(3):2473-80. doi: 10.1007/s13277-013-1327-5. Epub 2013 Nov 12.</citation>
    <PMID>24218336</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Effrossyni Votta-Velis</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Enzymatic Activity</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Chemokines</keyword>
  <keyword>Gene Expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT04048278/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT04048278/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

